Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1 1

Status

Recruiting 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Disease Progression 1

Interventions

Magnetic Resonance Spectroscopy 28enzalutamide 27Specimen Handling 21apalutamide 18Androgen Antagonists 16Prednisone 15Abiraterone Acetate 15Radiosurgery 13abiraterone 11Radiotherapy 10Docetaxel 10Biopsy 9darolutamide 8Pluvicto 8Nivolumab 8niraparib 6cabazitaxel 6Surveys and Questionnaires 6Radiation 6Lutetium-177 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6gallium 68 PSMA-11 5bicalutamide 5Radiotherapy, Intensity-Modulated 5Lutetium 5Gonadotropin-Releasing Hormone 5radium Ra 223 dichloride 4pembrolizumab 4luprolide acetate gel depot 4cabozantinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × Multiparametric Magnetic Resonance Imaging × 30 days × Clear all
NCT03388619 2026-05-27

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
30 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT04692675 2026-05-06

Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase NA Recruiting
508 enrolled
Genitourinary

Prostatic Neoplasms, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡